Qualify for a free subscription to HealthLeaders magazine.
Technology: Fluorescence-Assisted Resection and Exploration System (FLARE)
Manufacturer: Currently licensed by GE Healthcare
Purpose: To aid physicians in determining whether they've removed all of a patient's cancerous tissue and to do so without harming surrounding structures.
Early adopter: Still in clinical trials; however, FLARE has been used to successfully visualize organs and body fluids of mice and map the lymph nodes of pigs, all in real time.
What it does: The portable system, consisting of a near-infrared (NIR) imaging system, a video monitor, and a computer, uses chemical dyes called NIR fluorophores that are designed to target specific structures such as cancer cells when injected into patients. When exposed to NIR light, which is invisible to the human eye, the dyes light up the cancer cells and are shown on a video monitor.
Potential Improvement: More comprehensive surgical removal of breast, prostate, and lung cancer whose tumor boundaries can be difficult to determine at advanced stages.
What's Next: The first human clinical trials began in summer 2008; broader clinical use of the device could occur within five years, the researchers estimate.
- MU Compliance Announcement Sparks Concern, Confusion
- New G-Codes to Pay Doctors for Broad Array of Non-Face-to-Face Care
- Scary Financial Challenges for 2014
- Telehealth Improves Patient Care in ICUs
- CMS Sets 2014 Pay Rates for Hospital Outpatient and Physician Services
- 1 in 5 CT Screenings for Lung Cancer Results in Overdiagnosis
- MGMA Urges 'End-to-End' ICD-10 Testing
- LifePoint Bolsters Presence in Michigan's Upper Peninsula
- States Rejecting Medicaid Expansion Forgo Billions in Federal Funds
- Douglas Hawthorne—A Chance to Do Something Big